Groups
Treatment/Dose (mg/mL)
TG
(mg/dl)
TC
(mg/dl)
HDL-C
(mg/dl)
LDL-C
(mg/dl)
vLDL-C
(mg/dl)
Atherogenic index
Normal Control 83.92
± 4.63
102.73
±5.52
37.6
± 5.84
48,35
±4.95
16.78
± 2.6
0.348
±0.078
Control + CAMBA (25mg/kg) 79.27
±  5.81
95.18
± 6.22
34.21
± 4.69
45.12
± 7.24
15.85
±4.10
0.364
±0.065
Control + CAMBA (25mg/kg) 76.56
± 6.09
90.39
± 4.64
39.07
± 6.24
36.00
± 4.71
15.31
± 3.6
0.292
±0.049
Diabetic Control 157.34
±9.77**
141.53
± 7.04**
24.33
± 5.46**
85.55
± 4.94**
31.48
± 6.9**
0.810
±0.083**
Diabetic +CAMBA (25mg/kg) 106.48
±  6.19**
137.50
± 5.26**
27.18
± 4.50**
89.02
± 6.11**
21.29
± 3.4**
0.593
±0.046*
Diabetic +CAMBA (25mg/kg) 86.25
± 4.02**
94.67
± 3.44**
33.75
± 6.38**
43.67
± 4.38**
17.25
±4.2**
0.407
±0.037**
Diabetic +Glibenclamide(5mg/kg) 77.28
± 6.86**
92.58
± 8.15**
35.02
± 7.53**
42.10
±5.72**
15.45
±3.6**
0.344
±0.026**
Values represent the mean ± SE (n=8). Diabetic control rats were compared with normal control rats. Experimental groups were compared with the diabetic control rats LDL-C (mg/dl) = TC-HDL-[TG / 5], vLDL-C(mg/dl) = [Triglycerides/5], Atherogenic index = log (TG/HDL-C)
• *Significantly different from control group at p< 0.05
• **Significantly different from control group at p< 0.01
Table 4: Effect of CAMBA on plasma triglyceride (TG), total Cholesterol (TC), HDL-cholesterol (HDL-C), LDL- cholesterol (LDLC), vLDL- cholesterol (vLDLC) and atherogenic index in control and experimental groups of rats.